41.56 USD
At close May 16, 4:00 PM EDT
1 day
0.00%
5 days
0.00%
1 month
0.00%
3 months
0.00%
6 months
0.00%
Year to date
0.00%
1 year
0.00%
5 years
201.16%
10 years
313.94%
 

About: Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.

Employees: 260

0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 5 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

36% more call options, than puts

Call options by funds: $5.1M | Put options by funds: $3.75M

33% more repeat investments, than reductions

Existing positions increased: 72 | Existing positions reduced: 54

19% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 31

8% more funds holding in top 10

Funds holding in top 10: 12 [Q3] → 13 (+1) [Q4]

2% more funds holding

Funds holding: 188 [Q3] → 192 (+4) [Q4]

1.6% more ownership

Funds ownership: 101.19% [Q3] → 102.79% (+1.6%) [Q4]

14% less capital invested

Capital invested by funds: $3.45B [Q3] → $2.96B (-$494M) [Q4]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$70
68%
upside
Avg. target
$87
110%
upside
High target
$109
162%
upside

5 analyst ratings

positive
100%
neutral
0%
negative
0%
Wells Fargo
Eva Fortea Verdejo
45% 1-year accuracy
5 / 11 met price target
114%upside
$89
Overweight
Maintained
8 May 2025
Needham
Ami Fadia
28% 1-year accuracy
44 / 157 met price target
100%upside
$83
Buy
Reiterated
9 Apr 2025
Guggenheim
Michael Schmidt
38% 1-year accuracy
17 / 45 met price target
162%upside
$109
Buy
Reiterated
28 Mar 2025
B of A Securities
Tazeen Ahmad
26% 1-year accuracy
8 / 31 met price target
68%upside
$70
Buy
Maintained
10 Mar 2025
HC Wainwright & Co.
Andrew Fein
29% 1-year accuracy
98 / 337 met price target
105%upside
$85
Buy
Reiterated
3 Mar 2025

Financial journalist opinion

Based on 6 articles about MRUS published over the past 30 days

Neutral
GlobeNewsWire
2 days ago
Merus Announces the Journal Publication of Petosemtamab Mechanism of Action
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Merus N.V.
Merus Announces the Journal Publication of Petosemtamab Mechanism of Action
Neutral
GlobeNewsWire
1 week ago
Merus to Present at BofA Securities 2025 Health Care Conference
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Merus N.V.
Merus to Present at BofA Securities 2025 Health Care Conference
Negative
Zacks Investment Research
1 week ago
Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates
Merus N.V. (MRUS) came out with a quarterly loss of $1.40 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to loss of $0.59 per share a year ago.
Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates
Neutral
GlobeNewsWire
1 week ago
Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update
- Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial ongoing with clinical data update at 2025 ASCO® Annual Meeting
Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update
Negative
Zacks Investment Research
1 week ago
Earnings Preview: Merus N.V. (MRUS) Q1 Earnings Expected to Decline
Merus (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Merus N.V. (MRUS) Q1 Earnings Expected to Decline
Neutral
GlobeNewsWire
3 weeks ago
Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting
- Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC interim clinical data selected for poster presentation
Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting
Positive
Seeking Alpha
1 month ago
Merus: Riding The Bispecific Wave In Oncology
Merus stands out in biotech with its innovative Biclonics and Multiclonics platforms, focusing on bispecific and multispecific antibodies, particularly petosemtamab. Strong financials with $724 million cash runway through 2028, allowing strategic R&D investments without immediate capital market pressures. Petosemtamab shows robust clinical data, receiving two FDA Breakthrough Therapy designations, indicating significant potential in treating HNSCC and other cancers.
Merus: Riding The Bispecific Wave In Oncology
Neutral
GlobeNewsWire
1 month ago
Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025 at 8:45 a.m. ET.
Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
Negative
Zacks Investment Research
2 months ago
Merus N.V. (MRUS) Reports Q4 Loss, Lags Revenue Estimates
Merus N.V. (MRUS) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.95. This compares to loss of $1.09 per share a year ago.
Merus N.V. (MRUS) Reports Q4 Loss, Lags Revenue Estimates
Neutral
GlobeNewsWire
2 months ago
Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update
-  Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC and petosemtamab monotherapy in 2/3L r/m HNSCC enrolling; expected to be substantially enrolled by YE25
Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update
Charts implemented using Lightweight Charts™